US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    Diamyd Medical will receive additional USD 3.2 million in connection with divestment of Companion Medical

    A milestone has been achieved in connection with the previously announced acquisition of  Companion Medical, Inc. by Medtronic plc. As previous shareholder in Companion Medial, Diamyd Medical will receive a part of the milestone payment, approximately USD 3.2 million, corresponding to approximately SEK 28 million. The amount is expected to be paid in January 2021. About Diamyd MedicalDiamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have

    Companion Medical receives FDA clearance

    Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announced today that Companion Medical,Inc receives 510(k) clearance from the FDA for the InPen® system, an intelligent insulin administration system and smartphone application. Diamyd Medical owns 8.5% of Companion Medical and holds the distribution rights for future products in the Nordic countries.Companion Medical’s InPen® is cleared in the US for use with Ely Lilly’s Humalog® or Novo Nordisk’s Novolog® rapid acting insulin. The InPen® application is cleared for Apple iOS and an Android version is planned for later in 2016. Companion

    Diamyd Medical increases investment in Companion Medical

    Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that Diamyd Medical increases its investment in Companion Medical by USD 150,000. This is done in connection with a financing transaction in which Eli Lilly invests USD 3 million in Companion.Diamyd Medical is a shareholder in the medical device company Companion Medical. Companion has announced that the company has completed a financing transaction in which Eli Lilly invests USD 3 million in Companion. The funding will be used to complete Companion’s development of an insulin injector pen connected to a

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media